Introduction
Sir Francis Avery Jones (FAJ-for once the abbreviation means something to everyone) has been actively involved in the practical and research aspects of management of peptic ulcer throughout his long and productive career. Some of FAJ's earliest publications (Avery Jones, 1939a Jones, and b, 1943 Jones, , 1947 deal with management of acute upper alimentary bleeding and he was instrumental in introducing modern concepts of fluid and electrolyte balance into the treatment of these acutely ill patients. Accurate diagnosis was always one of FAJ's interests and in addition to exploiting together with F. Pygott the potential of the emergency barium meal, he did research in the field of endoscopy (Fletcher and Avery Jones, 1945) . The endoscopy sessions at Central Middlesex Hospital, before the introduction of fibreoptic instruments made life much easier for practitioners of this art, were one of the focal points of the week, with FAJ enjoying the doing and the teaching, usually with a large group of acolytes in attendance.
FAJ's contribution in the peptic ulcer area include not only research into the treatment and prognosis of complications of the disease (Avery Jones and Doll 1953; Avery Jones, 1956 ), but he also encouraged the then novel and revolutionary approach to the statistical evaluation of the results of treatment through the controlled therapeutic trial. Working in the Department of Gastroenterology at Central Middlesex Hospital Dr (now Sir) Richard Doll was given facilities to conduct the studies that eventually culminated in evaluating the first agent shown to significantly accelerate the healing of gastric ulcer (GU)-carbenoxolone sodium (Doll et aL, 1962) . Environmental factors, such as smoking, were also investigated (Doll, Avery Jones and Pygott, 1958) and FAJ's sustained interest in carbenoxolone is documented in serial publications (Avery Jones and Sullivan, 1972 ; Avery Jones and Parke, 1975; Avery Jones, Langman and Mann, 1978) .
These important researches established the background for the rapid progress and far-reaching changes in management of peptic ulcer that have taken place during the past 10 years. Progress in this area has been due to several factors. The development of fibreoptic endoscopy has improved the accuracy of diagnosis and the assessment of the effects of treatment on the healing of ulcers. The use of controlled clinical trials for evaluation of treatment has lead to a vast accumulation of data on ulcer healing under various medical regimes. Only those trials which take complete ulcer healing as the endpoint of treatment should be considered as valid. This is because endoscopic measurements of ulcer size are inaccurate and also because a partly healed ulcer is a doubtful therapeutic benefit.
Further progress in the medical management of duodenal ulcer (DU) and GU has been due to a fresh interest in the pharmacology of ulcer-healing drugs. The development of agents that powerfully inhibit gastric acid secretion by blocking the action of endogenous histamine at H2 receptors, or by blocking H+K+ATPase in parietal cells has led to intense research activity. This has produced a wealth of new data, new drugs and new insights into older remedies, sometimes with unexpected results. Faster healing of DU or GU is now attainable with many drugs. Moreover, medical treatment has for the first time been able to decrease significantly the relapse rate of DU and GU. The number of therapeutic strategies available for the management of DU or GU has increased, making the decision making process more interesting, but also more difficult. (Chierichetti, Gaetani and Petrin, 1979) .
Pirenzepine has been shown in a number of trials to have a similar effect on DU healing as cimetidine (Doll, Hill and Hutton, 1965) . Carbenoxolone has now declined in importance in comparison with newer, safer compounds. The mode of action has not been worked out in detail, but available evidence suggests that it slows down gastric epithelial cell turnover, alters the chemical composition of mucus and affects the metabolism of prostaglandins. It may also have antiviral properties.
Carbenoxolone is presumed to act topically on the ulcer-hence its presentation as tablets for the treatment of GU and as 'positioned release' capsules for the treatment of DU. Table 3 sets out results of controlled short-term trials in DU or GU. The results are comparable to those attained with other drugs. The main limitation to the use of carbenoxolone sodium in routine shortterm treatment of DU or GU are the unwanted effects, which comprise sodium and water retention, hypertension and hypokalaemia. These are potentially dangerous, necessitate careful and frequent supervision of the patient, and are especially marked in the elderly and in those with cardiorespiratory or renal insufficiency. Attempts to separate the unwanted from the therapeutic effects ofcarbenoxolone by treatment with aldosterone antagonists (spironolactone) (Doll, Langman and Shawdon, 1968) , or by synthesizing analogues ofcarbenoxolone, have not so far been successful (Fraser et al, 1972) . Controlled long-term trials of carbenoxolone therapy are not available.
Sucralfate
Sucralfate joins the range of mucosal protective drugs available for the treatment of DU. The drug, an aluminium salt of a sulphated disaccharide, is not absorbed and is presumed to act locally, protecting the ulcer crater from the damaging effects of acid, pepsin or bile. Moshal, Spitaels and Khan (1980) and others, in studies involving 328 patients, have shown healing rates of DU treatment with sucralfate ranging from 75 to 98%, compared to 44 to 66% healing on placebo. Comparisons of sucralfate with cimetidine in DU (Table 4) have yielded similar results (Martin et al., 1982) . In a 6-month maintenance study, Classen et aL (1982) reported a recurrence rate of22% on sucralfate and 51% on placebo in 122 DU patients, a significant difference. By contrast, sucralfate 2 g daily and placebo given for 6 months to 55 patients with GU yielded similar results. Only minor side effects have been reported so far and the drug One multicentre study in the U.K. and Ireland compared the effect of cimetidine 1 g/day with cimetidine 400 mg twice daily in the short-term treatment of DU (Kerr, 1981, Table 6 ). There was no difference between the results of the two doses of cimetidine, but before accepting these results more studies in other centres are needed.
Short-term treatment of DU with ranitidine consists of twice daily administration of 150 mg of this more powerful drug. Results are similar to those with cimetidine, and up to now all studies comparing ranitidine with placebo show a significant advantage for the active treatment (Table 7) . Comparisons of ranitidine 150 mg bd with cimetidine 1 g/day yield very similar results with either drug (Table 7) : in one large trial (Zeitoun and d'Azemar, 1982) ranitidine was just significantly better than cimetidine (P<0 05). Short-term treatment of GU Short-term treatment of chronic benign GU with H2 histamine receptor antagonists gives somewhat variable results (Table 8) . Not all trials of cimetidine versus placebo show an advantage for the active treatment. In general, cimetidine and carbenoxolone perform equally well in the short-term management of GU, but cimetidine is safer (Table 8) . A large multicentre trial shows ranitidine to have a significant advantage over dummy tablets, while comparisons of ranitidine versus cimetidine yield virtually identical results (Table 8) .
A TPase inhibitors Omeprazole This is the latest, and most powerful, addition to the range of drugs that decrease gastric acid secretion. Omeprazole is a substituted benzimidazole, which acts by inhibiting the H+K+ATPase at the secretory membrane of the parietal cell, and thus inhibits the proton pump. Omeprazole can produce complete inhibition of pentagastrin-stimulated acid output (Lind et al., 1983) and can virtually eliminate intragastric acidity in patients with DU eating normal meals (Walt et al., 1983) ; early results of short-term clinical trials in DU look promising (Gustavsson et al., 1983) .
Which drugfor short-term treatment ofpeptic ulcer?
There is thus now a very wide range of drugs listed in Table 9 available for the short-term (4-12 weeks) management of peptic ulcer. Despite profound differences in the pharmacological properties of these agents, the short-term results appear very similar ( Table 9 ). The choice of short-term therapy for peptic ulcer might therefore be governed not so much by efficacy, which appears to be similar, but by safety, Published experience of long-term maintenance trials with H2 histamine receptor antagonists in GU is less abundant. Each of three studies comprising a total of 75 patients with healed GU given 0-8 or 1 g of cimetidine daily for one year reported a significantly lower relapse rate (0-18%) on cimetidine than on placebo (44-64%) (Birger Jensen et al., 1979; Kang, Canalese and Piper, 1979; Machell et al., 1979) .
However, in another 6-month trial on 31 GU patients, cimetidine 800 mg daily was no better than placebo in preventing GU relapse (La Brooy et al., 1980) . The relapse rate of GU on ranitidine 150 mg at night for 6 months was 7% (1 of 15 patients), while it was 44% (7 of 16 patients) on placebo. An open, multicentre study showed a cumulative relapse rate of GU on ranitidine of 17% at one year (Cockel, Dawson and Jain, 1982 Now that there is a choice between surgical and medical management of uncomplicated DU, the decision whether or not to operate has to be arrived at with the fullest participation of the patient, following a careful and detailed explanation of advantages and disadvantages of each course of action. In GU most physicians would still advise early operation if the ulcer does not heal, or recurs after a period of medical treatment.
Modem medical management of peptic ulcer is now seen to provide opportunities of treatment with many drugs possessing widely differing pharmacological properties and modes of action. In the short term, these compounds alter the balance between attack by acid, pepsin, bile and other environmental and intraluminal agents on the one hand, and mucosal defence on the other. This heals ulcer in most patients. Healing can be maintained by longterm therapy with ranitidine, or cimetidine, but there is no evidence that the natural history of ulcer disease is affected and the relapse rate is appreciable. The long-term effect on the incidence of surgery in peptic ulcer is as yet unknown, although decreased rates of ulcer operations have been reported from various centres. Another factor may be a change in the clinical attributes of peptic ulcer diathesis. Despite all these changes and advances, the principles established by FAJ of early and accurate diagnosis and vigorous, scientifically based treatment, remain valid. The close cooperation between medical and surgical gastroenterologists which has been FAJ's practice in his Department at Central Middlesex Hospital continues to be important in the treatment of patients with acid-pepsin disease.
